EHA 2025 | Real-world outcomes for US patients with LR-MDS treated with first-line luspatercept

Low-risk MDS is a community disease in the United States, meaning that most of the patients are going to be seen by physicians in the community. And I think it’s very important for these physicians to have additional data, data that we’ve already published from COMMANDS. But I think seeing some real-world evidence to support COMMANDS was very important. And so luspatercept was FDA approved in August of 2020. So we wanted to see patients who had low-risk MDS, who had either received first-line luspatercept or ESA, and we were interested to look at their outcomes. And our primary endpoint was a composite endpoint evaluating RBC transfusion independence for greater than 12 weeks, in addition to an increase in hemoglobin greater than 1.5 grams per deciliter in the first six months. And what we found strongly supports COMMANDS. Luspatercept was efficacious across multiple subgroups. Most importantly, ring sideroblast positive, ring sideroblast negative, EPO levels greater than 200, in addition to those who had EPO levels less than 200 and were RS negative. And so I think, you know, take home from this is that our data strongly supports COMMANDS. Luspatercept is efficacious across multiple subgroups in low-risk MDS and should be considered as the frontline therapy in low-risk MDS.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.